20 studies found for:    "Diffuse systemic sclerosis"
Show Display Options
RSS Create an RSS feed from your search for:
"Diffuse systemic sclerosis"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting IL1-TRAP, Rilonacept, in Systemic Sclerosis
Conditions: Scleroderma;   Systemic Sclerosis;   Diffuse Scleroderma;   Diffuse Systemic Sclerosis
Interventions: Drug: Rilonacept;   Drug: Placebo
2 Not yet recruiting A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
Condition: Diffuse Cutaneous Systemic Sclerosis
Interventions: Drug: Abatacept;   Drug: Placebo
3 Unknown  Serial Night Time Position Splint on Systemic Sclerosis
Condition: Diffuse Systemic Sclerosis
Interventions: Device: Serial night time position splint;   Drug: Drug treatment
4 Completed Fresolimumab In Systemic Sclerosis
Condition: Diffuse Systemic Sclerosis
Intervention: Drug: Fresolimumab
5 Completed A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma
Conditions: Limited Scleroderma;   Diffuse Scleroderma
Intervention:
6 Recruiting IVIG Treatment in Systemic Sclerosis
Conditions: Systemic Sclerosis;   Diffuse Scleroderma
Intervention: Biological: Privigen
7 Unknown  Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Ambrisentan with an anti-fibrotic agent to assess benefit on skin.
8 Recruiting Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Drug: Belimumab
9 Unknown  High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic Sclerosis
Condition: Scleroderma, Diffuse
Intervention: Drug: N-acetylcysteine (NAC)
10 Completed Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
11 Unknown  AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis
Condition: Systemic Sclerosis
Interventions: Drug: Hyperimmune caprine serum;   Drug: Albumin
12 Completed Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma
Condition: Systemic Sclerosis
Intervention: Drug: Relaxin
13 Completed Mycophenolate Mofetil in Systemic Sclerosis
Condition: Diffuse Cutaneous Systemic Sclerosis
Intervention: Drug: Mycophenolate Mofetil
14 Terminated Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma
Condition: Scleroderma
Interventions: Drug: Imatinib mesylate;   Other: Placebo
15 Recruiting Highdose Chemotherapy and Transplantation of 34+ Selected Stem Cell for Progressive Systemic Sclerosis - Modification According to Manifestation
Conditions: Scleroderma;   Cardiac Involvement;   Autologous Stem Cell Transplantation
Intervention: Drug: Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells
16 Terminated Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis
Condition: Scleroderma, Systemic
Interventions: Drug: Thalidomide;   Drug: Placebo thalidomide
17 Completed Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis
Condition: Systemic Sclerosis
Interventions: Drug: anti-thymocyte globulin;   Drug: cyclophosphamide
18 Completed A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
Conditions: Scleroderma, Diffuse;   Scleroderma, Systemic
Intervention: Drug: Abatacept
19 Completed Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Drug: relaxin
20 Completed Proof of Biological Activity of SAR100842 in Systemic Sclerosis
Condition: Systemic Sclerosis
Interventions: Drug: SAR100842;   Drug: Placebo

Indicates status has not been verified in more than two years